UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031101
Receipt number R000035513
Scientific Title A confirmation study for improving effects of probiotics and synbiotics on intestinal environment in healthy adults.
Date of disclosure of the study information 2019/06/30
Last modified on 2019/06/06 16:03:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A confirmation study for improving effects of probiotics and synbiotics on intestinal environment in healthy adults.

Acronym

A confirmation study for improving effects of probiotics and synbiotics on intestinal environment.

Scientific Title

A confirmation study for improving effects of probiotics and synbiotics on intestinal environment in healthy adults.

Scientific Title:Acronym

A confirmation study for improving effects of probiotics and synbiotics on intestinal environment.

Region

Japan


Condition

Condition

Subjects with a tendency for constipation

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effect of bifidobacterium GCL2505 and bifidobacterium GCL2505 with inulin on gut bifidobacteria and intestinal environment of subjects with a tendency for constipation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

fecal bifidobacteria

Key secondary outcomes

defecation days, defecation frequency


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of test drink containing bifidobacterium GCL2505 (concentration of 1 X 10^10 CFU) for 2 weeks - Washout 2 weeks.

Interventions/Control_2

Intake of test drink containing bifidobacterium GCL2505 (concentration of 1 X 10^10 CFU) and inulin (2g) for 2 weeks - Washout 2 weeks.

Interventions/Control_3

Intake of placebo drink (not containing bifidobacterium GCL2505 and inulin) for 2 weeks - Washout 2 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects whose defecation frequency is no fewer than 2, nor more than 5.
2. Subjects who usually have three meals a day.

Key exclusion criteria

1. Subjects who regularly use intestinal drugs and laxatives (including strong laxatives).
2. Subjects who regularly intake healthy food to relieve constipation.
3. Subjects who use medicine such as antibiotics that affect digestion and absorption.
4. Subjects who can't stop intake food containing viable bacteria such as Lactic acid bacteria, Bifidobacteria, Natto bacteria and/or enhanced with oligosaccharide, dietary fiber and/or the health food to relieve constipation (including Food for Specified Health Uses (FOSHU)) and/or containing a large amount of sugar alcohol during this study.
5. Subjects who have allergic to food.
6. Subjects who have serious diseases requiring an urgent treatment, or who accept severe complication.
7. Subjects who has a medical history of diseases or surgeries affecting digestion, absorption and bowel movement.
8. Subjects are judged unsuitable for this study based on subject questionnaire.
9. Subjects who is pregnant or willing to be pregnant or breast-feeding during this study
10. Subjects who has a current or history of drug dependence and/or alcoholism.
11. Subjects who are participated in other clinical trials that intake/apply any of food, drug, and cosmetics, or willing to be that
12. Subjects who are judged unsuitable for this study by principal investigator

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Satoru
Middle name
Last name Suzuki

Organization

Shinagawa Season Terrace Health Care Clinic

Division name

Medical examination and treatment management family chief director

Zip code

108-0075

Address

1-2-70, Konan, Minato-ku, Tokyo, Japan

TEL

+81-3-3452-3381

Email

satoru_suzuki@sempos.or.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Yoshikawa

Organization

KSO Co., Ltd

Division name

Sales department

Zip code

105-0023

Address

1-9-7 Shibaura, Minato-ku, Tokyo, Japan

TEL

+81-3-3542-7733

Homepage URL


Email

yoshikawa@kso.co.jp


Sponsor or person

Institute

KSO Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

Ezaki Glico Co., Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Shinagawa Season Terrace Health Care Clinic

Address

1-2-70, Konan, Minato-ku, Tokyo, Japan

Tel

+81-3-3452-3381

Email

tomohiro_kogo@sempos.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 06 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 12 Month 22 Day

Date of IRB

2017 Year 12 Month 22 Day

Anticipated trial start date

2018 Year 02 Month 04 Day

Last follow-up date

2018 Year 05 Month 07 Day

Date of closure to data entry

2018 Year 06 Month 26 Day

Date trial data considered complete

2018 Year 07 Month 11 Day

Date analysis concluded

2018 Year 07 Month 30 Day


Other

Other related information



Management information

Registered date

2018 Year 02 Month 01 Day

Last modified on

2019 Year 06 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035513


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name